Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4024) 4024
Publication (229) 229
Book Review (76) 76
Newsletter (38) 38
Magazine Article (17) 17
Book Chapter (14) 14
Book / eBook (4) 4
Newspaper Article (2) 2
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (3342) 3342
humans (3204) 3204
medroxyprogesterone acetate (1674) 1674
middle aged (1363) 1363
medroxyprogesterone acetate - administration & dosage (1342) 1342
adult (1315) 1315
obstetrics & gynecology (1157) 1157
index medicus (954) 954
animals (714) 714
medroxyprogesterone - administration & dosage (696) 696
aged (612) 612
contraceptive agents, female - administration & dosage (571) 571
women (536) 536
medroxyprogesterone - analogs & derivatives (523) 523
pregnancy (512) 512
medroxyprogesterone acetate - adverse effects (500) 500
male (484) 484
hormone replacement therapy (476) 476
postmenopausal women (474) 474
medroxyprogesterone (457) 457
adolescent (425) 425
menopause (411) 411
estradiol - administration & dosage (408) 408
estrogen (407) 407
progesterone (407) 407
estrogen replacement therapy (398) 398
medroxyprogesterone acetate - pharmacology (378) 378
administration, oral (364) 364
medroxyprogesterone acetate - therapeutic use (363) 363
estrogens, conjugated - administration & dosage (362) 362
time factors (360) 360
postmenopause (350) 350
oncology (348) 348
medroxyprogesterone - pharmacology (345) 345
contraception (333) 333
drug administration schedule (329) 329
prospective studies (327) 327
endocrinology & metabolism (324) 324
contraceptive agents, female - adverse effects (314) 314
delayed-action preparations (309) 309
risk factors (303) 303
injections, intramuscular (287) 287
treatment outcome (285) 285
risk (284) 284
medroxyprogesterone - therapeutic use (276) 276
breast neoplasms - drug therapy (274) 274
estradiol (274) 274
drug therapy, combination (269) 269
double-blind method (248) 248
reproductive biology (248) 248
dose-response relationship, drug (246) 246
depot medroxyprogesterone acetate (245) 245
rats (245) 245
hormone therapy (233) 233
health aspects (232) 232
obstetrics and gynecology (230) 230
administration, cutaneous (219) 219
estrogen replacement therapy - adverse effects (219) 219
antineoplastic combined chemotherapy protocols - therapeutic use (217) 217
medroxyprogesterone - adverse effects (214) 214
young adult (205) 205
medicine, general & internal (202) 202
progestins - administration & dosage (197) 197
cancer (188) 188
norethindrone - administration & dosage (187) 187
bone density - drug effects (186) 186
research (186) 186
follow-up studies (183) 183
estradiol - blood (182) 182
estradiol - pharmacology (180) 180
replacement therapy (171) 171
norethindrone - analogs & derivatives (170) 170
estrogens - administration & dosage (169) 169
progesterone congeners - administration & dosage (165) 165
estrogen replacement therapy - methods (164) 164
progestin (160) 160
drug combinations (158) 158
randomized controlled-trial (153) 153
estradiol - analogs & derivatives (148) 148
analysis (147) 147
breast cancer (147) 147
endometrium - drug effects (145) 145
article (144) 144
clinical trials as topic (142) 142
therapy (141) 141
oral-contraceptives (139) 139
mice (138) 138
ovariectomy (138) 138
injections (137) 137
depot-medroxyprogesterone acetate (136) 136
conjugated equine estrogens (135) 135
hormones (134) 134
pharmacology & pharmacy (134) 134
birth control (133) 133
levonorgestrel - administration & dosage (131) 131
estrogens, conjugated - therapeutic use (130) 130
breast neoplasms - pathology (127) 127
breast-cancer (127) 127
progestins (126) 126
randomized controlled trials as topic (125) 125
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3766) 3766
Japanese (139) 139
German (47) 47
Spanish (31) 31
French (30) 30
Italian (24) 24
Chinese (15) 15
Polish (13) 13
Dutch (6) 6
Czech (5) 5
Danish (5) 5
Portuguese (5) 5
Russian (5) 5
Hungarian (3) 3
Swedish (2) 2
Korean (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women
by Yang, Liying and Hao, Yuhan and Hu, Jiyuan and Kelly, Dervla and Li, Huilin and Brown, Stuart and Tasker, Carley and Roche, Natalie E and Chang, Theresa L and Pei, Zhiheng
Emerging microbes & infections, ISSN 2222-1751, 2019, Volume 8, Issue 1, pp. 197 - 210
The use of depot medroxyprogesterone acetate (DMPA), a 3-monthly injectable hormonal contraceptive, is associated with an increased risk of HIV acquisition... 
HIV acquisition | Vaginal microbiome | depot medroxyprogesterone acetate | bacterial vaginosis-associated bacteria | network | AFRICAN WOMEN | PROSTATE-SPECIFIC ANTIGEN | FLORA | SUSCEPTIBILITY | RISK | MICROBIOLOGY | IMMUNOLOGY | BACTERIAL VAGINOSIS | HORMONAL CONTRACEPTION | IMMUNE | SEXUALLY-TRANSMITTED INFECTIONS | Lactobacillus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization
by Kuang, Yanping, M.D and Chen, Qiuju, Ph.D and Fu, Yonglun, M.D and Wang, Yun, M.D and Hong, Qingqing, M.D and Lyu, Qifeng, Ph.D and Ai, Ai, M.D and Shoham, Zeev, M.D
Fertility and Sterility, ISSN 0015-0282, 2015, Volume 104, Issue 1, pp. 62 - 70.e3
Objective To investigate the use of medroxyprogesterone acetate (MPA) to prevent LH surge during controlled ovarian hyperstimulation (COH) and to compare cycle... 
Internal Medicine | Obstetrics and Gynecology | Medroxyprogesterone acetate | premature LH surge | controlled ovarian stimulation | MENSTRUAL-CYCLE | ACTIVATION | STIMULATION | PROGESTERONE | RHESUS-MONKEY | MIFEPRISTONE | OBSTETRICS & GYNECOLOGY | GONADOTROPIN SURGE | REPRODUCTIVE BIOLOGY | ESTRADIOL | MIDCYCLE | BLOCKADE | Prospective Studies | Luteinizing Hormone - blood | Administration, Oral | Humans | Contraceptive Agents, Female - administration & dosage | Pregnancy | Luteinizing Hormone - antagonists & inhibitors | Ovulation Induction - methods | Fertilization in Vitro - methods | Female | Medroxyprogesterone Acetate - administration & dosage | Oocyte Retrieval - methods | Infertility, Female - diagnosis | Infertility, Female - therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effects of Depot Medroxyprogesterone Acetate Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial
by Raymond, Elizabeth G and Weaver, Mark A and Louie, Karmen S and Tan, Yi-Ling and Bousiéguez, Manuel and Aranguré-Peraza, Ana Gabriela and Lugo-Hernández, Elba M and Sanhueza, Patricio and Goldberg, Alisa B and Culwell, Kelly R and Kaplan, Clair and Memmel, Lisa and Sonalkar, Sarita and Jamshidi, Roxanne and Winikoff, Beverly
Obstetrics and Gynecology, ISSN 0029-7844, 10/2016, Volume 128, Issue 4, pp. 739 - 745
OBJECTIVE:To evaluate the effects of timing of depot medroxyprogesterone acetate injection on medical abortion outcome and risk of repeat pregnancy within the... 
CONTRACEPTIVE IMPLANT | MIFEPRISTONE | OBSTETRICS & GYNECOLOGY | Abortifacient Agents, Steroidal - administration & dosage | Humans | Contraceptive Agents, Female - administration & dosage | Treatment Outcome | Injections, Intramuscular | Delayed-Action Preparations - administration & dosage | Patient Satisfaction | Pregnancy | Young Adult | Abortion, Induced - adverse effects | Time Factors | Adolescent | Adult | Female | Medroxyprogesterone Acetate - administration & dosage | Pregnancy Rate | Mifepristone - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine Device
by van Hylckama Vlieg, Astrid and Helmerhorst, Frans M and Rosendaal, Frits R
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 11/2010, Volume 30, Issue 11, pp. 2297 - 2300
OBJECTIVE—To assess the risk of venous thrombosis associated with nonoral contraceptives (ie, injectable depot–medroxyprogesterone acetate contraceptives,... 
nonoral contraceptives | risk factors | hormone-releasing IUD | injectable DMPA | venous thrombosis | SYSTEM | WOMEN | COAGULATION | PERIPHERAL VASCULAR DISEASE | THROMBOEMBOLISM | USERS | HEMATOLOGY | ORAL-CONTRACEPTIVES | Contraceptive Agents, Female - adverse effects | Venous Thrombosis - chemically induced | Humans | Middle Aged | Risk Factors | Contraceptive Agents, Female - administration & dosage | Intrauterine Devices - adverse effects | Case-Control Studies | Venous Thrombosis - etiology | Young Adult | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Adolescent | Medroxyprogesterone Acetate - adverse effects | Adult | Female | Medroxyprogesterone Acetate - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The pregnancy outcome of progestin‐primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial
by Dong, J and Wang, Y and Chai, WR and Hong, QQ and Wang, NL and Sun, LH and Long, H and Wang, L and Tian, H and Lyu, QF and Lu, XF and Chen, QJ and Kuang, YP
BJOG: An International Journal of Obstetrics & Gynaecology, ISSN 1470-0328, 06/2017, Volume 124, Issue 7, pp. 1048 - 1055
An RCT confirmed similar pregnancy outcome in P‐primed ovarian stimulation with a daily dose of 4 or 10 mg MPA . 
Controlled ovarian stimulation | luteinising hormone surge | progestin | HYPERSTIMULATION | ACTIVATION | GONADOTROPIN-SECRETION | RHESUS-MONKEY | OBSTETRICS & GYNECOLOGY | DISCHARGE | LUTEINIZING-HORMONE SURGES | GNRH ANTAGONIST | CYCLES | THAWED EMBRYO-TRANSFER | BLOCKADE | Luteinizing Hormone - blood | Humans | Treatment Outcome | Pregnancy Outcome - epidemiology | Pregnancy | Young Adult | Chorionic Gonadotropin - administration & dosage | Embryo Transfer | Ovulation Induction - methods | Progestins - administration & dosage | Fertilization in Vitro - methods | Adult | Female | Medroxyprogesterone Acetate - administration & dosage | Oocyte Retrieval - methods | Infertility, Female - therapy | Medroxyprogesterone | Glycoproteins | Chorionic gonadotropin | Hormones | Pregnant women
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): A systematic review
by Dragoman, Monica V and Gaffield, Mary E
Contraception, ISSN 0010-7824, 2016, Volume 94, Issue 3, pp. 202 - 215
Abstract Context Depot medroxyprogesterone acetate (DMPA), a progestogen-only contraceptive injectable, has traditionally been formulated as a crystalline... 
Obstetrics and Gynecology | DMPA | Safety | Subcutaneous | Depot medroxyprogesterone | Progestogen-only injectables | BONE-MINERAL DENSITY | ENDOMETRIOSIS-ASSOCIATED PAIN | EXTREMELY OBESE WOMEN | LEUPROLIDE ACETATE | OBSTETRICS & GYNECOLOGY | CLINICAL-RESEARCH | CONTRACEPTIVE EFFICACY | SAYANA(R) PRESS | PHARMACOKINETICS | INJECTION | INTRAMUSCULAR DMPA | Contraceptive Agents, Female - adverse effects | World Health Organization | Obesity - complications | Humans | Contraceptive Agents, Female - administration & dosage | Injections, Intramuscular | Pain - chemically induced | Endometriosis - complications | Delayed-Action Preparations - administration & dosage | Patient Satisfaction | Randomized Controlled Trials as Topic | Bone Density - drug effects | Injections, Subcutaneous | HIV Infections - complications | Medroxyprogesterone Acetate - adverse effects | Female | Weight Gain - drug effects | Medroxyprogesterone Acetate - administration & dosage | Practice Guidelines as Topic | Medroxyprogesterone | Safety and security measures
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain
by Crosignani, P.G and Luciano, A and Ray, A and Bergqvist, A
Human Reproduction, ISSN 0268-1161, 01/2006, Volume 21, Issue 1, pp. 248 - 256
BACKGROUND: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain.... 
Endometriosis | Bone mineral density | Depot medroxyprogesterone acetate | Subcutaneous injection | Pelvic pain | Leuprolide | PLACEBO | endometriosis | depot medroxyprogesterone acetate | CONTRACEPTION | OBSTETRICS & GYNECOLOGY | SYMPTOMATIC ENDOMETRIOSIS | bone mineral density | REPRODUCTIVE BIOLOGY | INFERTILE WOMEN | subcutaneous injection | DOUBLE-BLIND | leuprolide | pelvic pain | QUALITY-OF-LIFE | DANAZOL | AROMATASE | SHORT-TERM | Contraceptive Agents, Female - adverse effects | Bone Density | Lumbar Vertebrae - diagnostic imaging | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Contraceptive Agents, Female - administration & dosage | Treatment Outcome | Administration, Cutaneous | Endometriosis - drug therapy | Uterine Diseases - drug therapy | Radiography | Antineoplastic Agents, Hormonal - adverse effects | Pelvic Pain - drug therapy | Leuprolide - administration & dosage | Medroxyprogesterone Acetate - adverse effects | Quality of Life | Adult | Female | Leuprolide - adverse effects | Hip - diagnostic imaging | Medroxyprogesterone Acetate - administration & dosage | Fertility Agents, Female - administration & dosage | Fertility Agents, Female - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Controlled ovarian stimulation using medroxyprogesterone acetate and hmg in patients with polycystic ovary syndrome treated for ivf: A double-blind randomized crossover clinical trial
by Wang, Yun and Chen, Qiuju and Wang, Ningling and Chen, Hong and Lyu, Qifeng and Kuang, Yanping
Medicine (United States), ISSN 0025-7974, 03/2016, Volume 95, Issue 9, p. e2939
Ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation is a current challenge for patients with polycystic ovarian syndrome (PCOS). Our previous... 
Embryo Transfer - methods | Prospective Studies | Double-Blind Method | Administration, Oral | Humans | Medroxyprogesterone Acetate - pharmacology | Menotropins - pharmacology | Polycystic Ovary Syndrome - physiopathology | Cross-Over Studies | Pregnancy | Sperm Injections, Intracytoplasmic | Ovulation Induction - methods | Fertilization - drug effects | Ovarian Hyperstimulation Syndrome - prevention & control | Fertilization in Vitro - methods | Adult | Female | Medroxyprogesterone Acetate - administration & dosage | Menotropins - administration & dosage | Gonadotropin-Releasing Hormone - agonists | Pregnancy Outcome | Luteinizing Hormone - secretion | Antagonists (Biochemistry) | Care and treatment | Usage | Stein-Leventhal syndrome | Health aspects | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Depot Medroxyprogesterone Acetate and Bone Mineral Density in Adolescents—The Black Box Warning: A Position Paper of the Society for Adolescent Medicine
by Cromer, Barbara A and Scholes, Delia and Berenson, Abbey and Cundy, Tim and Clark, M. Kathleen and Kaunitz, Andrew M and Society for Adolescent Medicine
Journal of Adolescent Health, ISSN 1054-139X, 2006, Volume 39, Issue 2, pp. 296 - 301
The purpose of this Position Paper is to review the published Black Box Warning regarding depot medroxyprogesterone acetate (DMPA) and bone loss as it relates... 
WOMEN | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HEALTHY-CHILDREN | PSYCHOLOGY, DEVELOPMENTAL | PEDIATRICS | HORMONE CONTRACEPTION | COHORT | RANDOMIZED CONTROLLED-TRIAL | USERS | GIRLS | ORAL-CONTRACEPTIVES | DECLINE | Contraceptive Agents, Female - adverse effects | Calcium, Dietary | United States | Humans | Contraceptive Agents, Female - administration & dosage | Adolescent Medicine | Contraindications | Bone Density - drug effects | Drug Labeling | Fractures, Bone - etiology | Societies, Medical | Adolescent | Counseling | Medroxyprogesterone Acetate - adverse effects | Female | Bone Resorption - chemically induced | Medroxyprogesterone Acetate - administration & dosage | Delayed-Action Preparations | United States Food and Drug Administration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Tenofovir Disoproxil Fumarate Intravaginal Ring Protects High-Dose Depot Medroxyprogesterone Acetate–Treated Macaques From Multiple SHIV Exposures
by Smith, James M and Srinivasan, Priya and Teller, Ryan S and Lo, Yungtai and Dinh, Chuong T and Kiser, Patrick F and Herold, Betsy C
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 01/2015, Volume 68, Issue 1, pp. 1 - 5
Preclinical HIV prevention models use either a single high-dose viral challenge in depot medroxyprogesterone acetate–treated macaques or repeated viral... 
macaque | PrEP | Depo-Provera | Intravaginal ring | TDF | HIV PREVENTION | INFECTIOUS DISEASES | EFFICACY | SAFETY | IMMUNOLOGY | CHALLENGES | ANIMAL-MODELS | intravaginal ring | INFECTION | PREEXPOSURE PROPHYLAXIS | TECHNOLOGY | HIV Infections - prevention & control | Macaca nemestrina | Adenine - analogs & derivatives | Vagina | Phosphorous Acids - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Simian Acquired Immunodeficiency Syndrome - prevention & control | Animals | Adenine - therapeutic use | Phosphorous Acids - therapeutic use | Placebos | Anti-HIV Agents - therapeutic use | Female | HIV Infections - transmission | Simian Acquired Immunodeficiency Syndrome - transmission | Medroxyprogesterone Acetate - administration & dosage | Delayed-Action Preparations | Macaque
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials
by Manson, JoAnn E and Chlebowski, Rowan T and Stefanick, Marcia L and Aragaki, Aaron K and Rossouw, Jacques E and Prentice, Ross L and Anderson, Garnet and Howard, Barbara V and Thomson, Cynthia A and LaCroix, Andrea Z and Wactawski-Wende, Jean and Jackson, Rebecca D and Limacher, Marian and Margolis, Karen L and Wassertheil-Smoller, Sylvia and Beresford, Shirley A and Cauley, Jane A and Eaton, Charles B and Gass, Margery and Hsia, Judith and Johnson, Karen C and Kooperberg, Charles and Kuller, Lewis H and Lewis, Cora E and Liu, Simin and Martin, Lisa W and Ockene, Judith K and O'Sullivan, Mary Jo and Powell, Lynda H and Simon, Michael S and Van Horn, Linda and Vitolins, Mara Z and Wallace, Robert B
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 2013, Volume 310, Issue 13, pp. 1353 - 1368
IMPORTANCE Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. OBJECTIVE... 
BREAST-CANCER | INSOMNIA RATING-SCALE | MEDICINE, GENERAL & INTERNAL | REPLACEMENT THERAPY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | ESTROGEN PLUS PROGESTIN | CORONARY-HEART-DISEASE | MILD COGNITIVE IMPAIRMENT | POSTMENOPAUSAL WOMEN | CONJUGATED EQUINE ESTROGEN | United States - epidemiology | Follow-Up Studies | Humans | Middle Aged | Coronary Disease - epidemiology | Risk | Hormone Replacement Therapy - adverse effects | Pulmonary Embolism - epidemiology | Estrogens - adverse effects | Medroxyprogesterone Acetate - adverse effects | Postmenopause | Female | Stroke - epidemiology | Drug Therapy, Combination | Breast Neoplasms - epidemiology | Colorectal Neoplasms - epidemiology | Estrogens, Conjugated (USP) - administration & dosage | Treatment Outcome | Endometrial Neoplasms - epidemiology | Hip Fractures - epidemiology | Breast Neoplasms - prevention & control | Coronary Disease - prevention & control | Quality of Life | Aged | Medroxyprogesterone Acetate - administration & dosage | Estrogens, Conjugated (USP) - adverse effects | Estrogens - administration & dosage | Women | Care and treatment | Research | Hormone therapy | Health aspects | Menopause | Womens health | Estrogen | Endocrine therapy | Clinical trials | Cardiovascular disease | Breast cancer | Progesterone | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate
by Beasley, Anitra and White, Katharine O'Connell and Cremers, Serge and Westhoff, Carolyn
Contraception, ISSN 0010-7824, 2014, Volume 89, Issue 5, pp. 352 - 356
Abstract Objectives To evaluate feasibility, acceptability, continuation, and trough serum levels following self-administration of subcutaneous (sc) depot... 
Obstetrics and Gynecology | Injectable | Self-administration | Contraception | Depot medroxyprogesterone acetate | INJECTION | ADOLESCENTS | ACCEPTABILITY | PROVERA | DISCONTINUATION | OBSTETRICS & GYNECOLOGY | Young Adult | Self Administration | Humans | Injections, Subcutaneous | Contraceptive Agents, Female - administration & dosage | Adult | Female | Medroxyprogesterone Acetate - administration & dosage | Feasibility Studies | Medroxyprogesterone | Clinical trials | injectable | depot medroxyprogesterone acetate | self-administration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study
by Cover, Jane and Ba, Maymouna and Lim, Jeanette and Drake, Jennifer Kidwell and Daff, Bocar M
Contraception, ISSN 0010-7824, 09/2017, Volume 96, Issue 3, pp. 203 - 210
Expanding contraceptive options through self-injection may improve access and confidentiality. There are few published studies on contraceptive self-injection... 
Home and self-injection | Self-administration | DMPA-SC | Family planning | Sayana® Press | Injectable contraception | Sayana (R) Press | SAYANA(R) PRESS | CONTRACEPTION | UGANDA | OBSTETRICS & GYNECOLOGY | Prospective Studies | Contraceptive Agents, Female - therapeutic use | Humans | Middle Aged | Contraceptive Agents, Female - administration & dosage | Medroxyprogesterone Acetate - therapeutic use | Feasibility Studies | Young Adult | Self Administration | Patient Acceptance of Health Care | Senegal | Injections, Subcutaneous | Adolescent | Adult | Female | Medroxyprogesterone Acetate - administration & dosage | Medroxyprogesterone | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Committee Opinion No. 602: Depot Medroxyprogesterone Acetate and Bone Effects
Obstetrics & Gynecology, ISSN 0029-7844, 06/2014, Volume 123, Issue 6, pp. 1398 - 1402
Depot medroxyprogesterone acetate (DMPA) is a highly effective injectable contraceptive that affords privacy and has a convenient dose schedule of four times... 
Contraceptive Agents, Female - adverse effects | Bone Density - physiology | Risk Assessment | Humans | Contraceptive Agents, Female - administration & dosage | Bone and Bones - drug effects | Pregnancy | Young Adult | Bone Density - drug effects | Drug Labeling | Adolescent | Counseling | Medroxyprogesterone Acetate - adverse effects | Adult | Female | Medroxyprogesterone Acetate - administration & dosage | Fractures, Bone - chemically induced | Delayed-Action Preparations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception
by Heffron, Renee and Mugo, Nelly and Were, Edwin and Kiarie, James and Bukusi, Elizabeth A and Mujugira, Andrew and Frenkel, Lisa M and Donnell, Deborah and Ronald, Allan and Celum, Connie and Baeten, Jared M and Robert W. Coombs, L.F and Kabwohe, Uganda and Jinja, Uganda and Hendrix, Craig W and Lingappa, Jairam and McElrath, M. Juliana and Kenya, Eldoret and Fife, Kenneth and Tumwesigye, Elioda and Kampala, Uganda and Elly Katabira, A.R and Kisumu, Kenya and Mbale, Uganda and Nairobi, Kenya and Ndase, Patrick and Katabira, Elly and Cohen, Craig and Wangisi, Jonathan and Campbell, James and Tappero, Jordan and Thika, Kenya and Tororo, Uganda and Farquhar, Carey and John-Stewart, Grace and Mugo, Nelly Rwamba and Partners PrEP Study Team
AIDS, ISSN 0269-9370, 2014, Volume 28, Issue 18, pp. 2771 - 2776
Objective: To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for... 
HIV-1 prevention | Depot medroxyprogesterone acetate | Hormonal contraception | Preexposure prophylaxis efficacy | hormonal contraception | INFECTIOUS DISEASES | TRANSMISSION | VIROLOGY | EPIDEMIOLOGIC EVIDENCE | ACQUISITION | RISK | INFECTION | depot medroxyprogesterone acetate | IMMUNOLOGY | preexposure prophylaxis efficacy | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Humans | Contraceptive Agents, Female - administration & dosage | Male | Treatment Outcome | Kenya | Delayed-Action Preparations - administration & dosage | Randomized Controlled Trials as Topic | Pregnancy | Anti-Retroviral Agents - administration & dosage | Adult | Female | Uganda | Medroxyprogesterone Acetate - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women
by Williams, Rebekah L and Hensel, Devon J and Fortenberry, J. Dennis
Contraception, ISSN 0010-7824, 2013, Volume 88, Issue 3, pp. 401 - 407
Abstract Background Intramuscular depot medroxyprogesterone acetate (DMPA-IM) is now available in subcutaneous (SC) formulation, potentially allowing for... 
Obstetrics and Gynecology | Self-injection | Contraception | Depot medroxyprogesterone acetate | Adolescent | INTERNET | CHLAMYDIA-TRACHOMATIS | VAGINAL SWABS | OBSTETRICS & GYNECOLOGY | Cross-Over Studies | Young Adult |